NCT04498169View on ClinicalTrials.gov

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

August 11, 2021

Study Completion Date

August 11, 2021

Conditions
Corneal Edema
Interventions
DRUG

Netarsudil Ophthalmic

Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

DRUG

Netarsudil Ophthalmic

Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

Trial Locations (12)

23502

Virginia Eye Consultants, Norfolk

41017

Cincinnati Eye Institute, Edgewood

43082

Comprehensive Eye Care, Westerville

55305

Minnesota Eye Care, Minnetonka

55420

Chu Vision Institute, Bloomington

57108

Vance Thompson Vision, Sioux Falls

58078

Vance Thompson Vision, West Fargo

63131

Ophthalmology Associates, St Louis

77025

Houston Eye Associates, Houston

92653

Harvard Eye Associates, Laguna Hills

92843

Orange County Ophthalmology, Garden Grove

02748

Advance Eye Associates, South Dartmouth

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT04498169 - A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy | Biotech Hunter | Biotech Hunter